Weight loss at the time of GLP-1 discontinuation was 10.1% overall, 9.7% for those with T2D, and 11.1% for those without.

Two phase 3 trials will study Kura Oncology’s ziftomenib for frontline acute myeloid leukemia, one with venetoclax and the ...

Covert operations, online takedowns, and multimillion-pound seizures – how regulators are tackling the criminal networks ...

Older adults with apparent hypothyroidism may or may not need treatment. This second article about thyroid disease in older ...

Some primary care clinics are investing in social needs programs to overcome barriers to care. New evidence shows how these ...

A new opinion paper shows no convincing evidence that there is a causal link between gut bacteria and autism, citing weak ...

Medication overuse is a major preventable driver of headache-related disability across the globe, highlighting the need for ...

A brief hypnosis session before surgery for breast cancer appears more effective than a mindfulness session in reducing ...

These studies represent promising new treatment options for chronic and progressive kidney diseases, offering renewed hope to ...

Dr Mark Kris discusses how a small 2015 study with just two nivolumab doses led to a wave of curative-intent trials.

Ethicist Art Caplan discusses FDA layoffs and their impact on protection of human research subjects in clinical trials.

A lower maintenance dose of peanut immunotherapy may provide similar effectiveness and an improved safety profile compared ...